Latest News Archive

Please select Category, Year, and then Month to display items

UFS Choirs Entertaining and Uplifting Staff and Students

25 March 2022 | Story Anthony Mthembu | Photo Supplied

The Bloemfontein Campus Choir singing in front of the Main Building for students in celebration of Human Rights Day.

Students on the Bloemfontein Campus were treated to a lunch-hour music performance by the campus choir – an uplifting musical production led by the indomitable Sibongile Mngoma, conductor of the choir on the Bloemfontein Campus. The performance, which was in celebration of Human Rights Day, took place on 22 March 2022 in front of the Main Building. “We realised that people were hungry to hear beautiful music and beautiful sounds, and we started these pop-up performances just to revive people’s spirit and to give them hope,” says Lucy Sehloho, Officer: Arts and Culture in the Department of Student Affairs. As such, the staff and students at the University of the Free State (UFS) can look forward to a series of pop-up performances by the UFS choirs, specifically on the Bloemfontein and South Campuses.

One institution, different sounds

According to Sehloho, “the choirs are all running on the same constitution and the same code of conduct”. However, they are slightly different in sound, and this is determined by the audience to whom the respective choirs cater, and the number of members involved in the choir. The Bloemfontein Campus choir is known to cover genres such as rap, trap, classical music, and South African choral music. However, the Qwaqwa Campus choir focuses on choral music and various African sounds, while the South Campus choir manoeuvres through most of the abovementioned genres.

Preparing for life as an artist after university

It is important to note that the choirs are not just a safe space that encourages expression for young artists. Indeed, for many students it is also the beginning of a career. As such, they are taught lessons about financial literacy and the ability to brand themselves as artists. “One of the things I am teaching the students is how to price and cost themselves,” Sehloho highlighted. In fact, Sehloho argues that a major challenge among young performers when they leave university, is that – because they have never charged a fee for their service – they have no idea how to price and sustain themselves from the money they acquire. Consequently, industry experts are invited to provide insight into the realities of the world for artists once they start working. These industry experts include Dr Jerry Mofokeng wa Makhetha.

Future endeavours for the respective choirs

In addition to these lessons, the choirs have various projects that they are working on. The Bloemfontein Campus choir is currently planning performances for national holidays such as Freedom Day and Youth Day. The choir is also gearing up for a performance of Handel’s Messiah in celebration of Easter. The South Campus is specifically working towards the Network Festival in collaboration with Oranje Girls’ School. Furthermore, the Bloemfontein Campus choir will compete in the Sing for Gold competition in Barcelona this coming October. Once an institutional choir has been finalised, the Arts and Culture team will represent the UFS and the nation at the World Choir Games in 2023.

The main challenge experienced by the choirs

Although the choirs are succeeding in entertaining and uplifting the UFS community, there are still some challenges that hinder their growth to some extent. Racial diversity is one of these barriers. ‘’When someone looks at the choir, they don’t get to see the full picture of who we as the University of the Free State are in terms of diversity,’’ she explains. Therefore, Sehloho notes that the respective choirs are open to students from all walks of life in order to ensure racial and cultural diversity. As such, students who are interested in joining can contact Lucy Sehloho at SehlohoLP@ufs.ac.za

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease

2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013

The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.

In future further evaluation will be performed in other forms of hypocholesterolemia.

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.

Back

Economic and Management Sciences

Education

Health Sciences

The Humanities

Law

Natural and Agricultural Sciences

Theology and Religion

Open Distance Learning

Business School

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept